Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | HRH2 | P25021 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959794 | 1.00 | CHRM3 (0.61) | CHRM3CHRM2ADRB2CHRM1KCNH2 | |
| SCHEMBL5425075 | 0.90 | CHRM3 (0.57) | CHRM3CHRM2ADRB2CHRM1KCNH2 | |
| SCHEMBL962503 | 0.90 | CHRM3 (0.57) | CHRM3CHRM2ADRB2CHRM1KCNH2 | |
| SCHEMBL4353701 | 0.90 | CHRM3 (0.57) | CHRM3CHRM2ADRB2CHRM1KCNH2 | |
| SCHEMBL5352925 | 0.90 | CHRM3 (0.57) | CHRM3CHRM2ADRB2CHRM1KCNH2 | |
| SCHEMBL962504 | 0.90 | CHRM3 (0.57) | CHRM3CHRM2ADRB2CHRM1KCNH2 | |
| SCHEMBL4353693 | 0.90 | CHRM3 (0.57) | CHRM3CHRM2ADRB2CHRM1KCNH2 | |
| SCHEMBL13590341 | 0.90 | CHRM3 (0.61) | CHRM3CHRM2ADRB2CHRM1KCNH2 | |
| SCHEMBL13590478 | 0.90 | CHRM3 (0.61) | CHRM3CHRM2ADRB2CHRM1KCNH2 | |
| SCHEMBL13592297 | 0.90 | CHRM3 (0.61) | CHRM3CHRM2ADRB2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008278-B2 | Diarylmethyl and related compounds | THERAVANCE, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110015152-A1 | DIARYLMETHYL AND RELATED COMPOUNDS | THERAVANCE, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-7829728-B2 | Diarymethyl and related compounds | THERAVANCE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080114030-A1 | Diarymethyl and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-05-15 | — | — | US | disclosed |
| US-7317102-B2 | Diarylmethyl and related compounds | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20060287369-A1 | Diarylmethyl and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114030-A1 | Diarymethyl and related compounds | ADRB2, ADRB1, ADRA2B | CHRM3 12/4885CHRM2 11/4885ADRB2 1/4885 |
| US-20060287369-A1 | Diarylmethyl and related compounds | ADRB2, ADRB1, ADRA2B | CHRM3 12/4885CHRM2 11/4885ADRB2 1/4885 |
| US-20110015152-A1 | DIARYLMETHYL AND RELATED COMPOUNDS | ADRB2, ADRB1, ADRA2B | CHRM3 12/4885CHRM2 11/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.